Drug · DIN 02527405
TABRECTA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 16, 2022; first marketed September 16, 2022.
- Drug Identification Number (DIN)
- 02527405
- Company (DIN owner)
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Capmatinib L01EP01
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| CAPMATINIB (CAPMATINIB HYDROCHLORIDE) | 200 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 26, 2022: NOC 30374New Drug Submission (NDS)
Other DINs named TABRECTA
- DIN 02527391 · Marketed